United States: FDLI's 2015 Annual Conference Educates A Record Crowd Part One Of Two

Last Updated: May 19 2015
Article by Brian J. Malkin

On April 20-21, 2015 the Food and Drug Law Institute (FDLI) held its Annual Conference in Washington, D.C., welcoming over 600 heavy hitters from both FDA, industry, consulting, and law firms featuring FDA practices. Following opening remarks by FDLI's President and CEO, Amy Comstock Rick, leading her first FDLI Annual Meeting, Acting FDA Commissioner Stephen Ostroff, M.D., took the stage. Ostroff said that it was his first time speaking at FDLI, day 14 as Acting Commissioner, and that he was fortunate to lead FDA after former Commissioner Margaret A. Hamburg, M.D. Ostroff highlighted FDA's 51 new molecular entity approvals last year (17 first-in-class, two-thirds approved first in the United States and utilizing at least one accelerated-type approval program). Ostroff noted that FDA has been inspecting more, with drug compounding as an "eye-opener," and described FDA's approval of the first biosimilar product as a "game changer." Ostroff said FDA will be tackling traditional animal husbandry by removing growth-promoting hormones to help prevent antimicrobial resistance. FDA will continue to consider opioid abuse and misuse, with more abuse-deterrent formulations under way. FDA will respond quickly, as additional diagnostics and measures are developed to combat the Ebola outbreaks. And FDA will continue to implement the Food Safety and Modernization Act, Ostroff said, which is "transformational," as well as new food labeling to help consumers make better informed choices. Finally, FDA is concerned about reducing harm from tobacco product with youths, Ostroff explained, especially for some new products under consideration in the deeming rule, such as e- cigarettes.

Following Ostroff, a reactor panel noted that FDA needs to consider ways that physicians, pharmacists, and consumers can have access to more than safety and efficacy information about products. Some viewed the Center for Devices and Radiologic Health (CDRH) as overregulating, especially by some reviewers, in a world where it is increasing difficult to find predicate products to take advantage of the 510(k) clearance process. With FSMA, FDA will need to offer training for inspectors, others noted. And some questioned whether FDA has the capability to understand substantially equivalent or modified-risk tobacco products.

A second keynote by Chief Counsel Elizabeth Dickinson reinforced that FDA is well worthy of the public trust. Dickinson provided an overview of the myriad of legal issues facing FDA and her office. Dickinson noted that FDA is grappling with opioid drug abuse, determining whether FDA can withdraw a product if the primary concern is abuse or misuse, as well as removing products from the market that inappropriately claim to treat or cure Ebola. Dickinson acknowledged that FSMA is an important developing area. At the same time, FDA is struggling to move forward with the deeming regulation, which is complicated by the need to respond to the 130,000 comments received, along with a reconstituted advisory committee for tobacco products, which was disbanded due to conflict issues. FDA recognizes how preemption laws are affecting product labeling approaches, Dickinson said, and FDA is considering other options to its proposed generic changes being effected proposal—one proposed by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Generic Pharmaceutical Association (GPhA) . FDA continues to have new exclusivity issues, Dickinson observed, from the scheduling issues raised by the not so contemporaneous Drug Enforcement Agency scheduling process, and new chemical entities, as well as determining the scope of 3-year clinical data exclusivity, and the possibility for pediatric labeling carve outs from products with orphan drug exclusivity. Amidst this, FDA is ramping up for another round of user fees and associated legislative changes at FDA. For some issues, such as 180-day exclusivity, FDA continues to regulate from the statute prior to regulations, with guidances taking an increasingly important role, Dickinson said. In the world of biosimilars, FDA is considering appropriate non-proprietary names and the transition provisions for certain biologics being reclassified from NDAs to BLAs in 2020. At the same time, the Office of Chief Counsel works on random problem solving, including reviewing the presentations delivered at FDLI, Dickinson explained. Dickinson said that she would not take questions but would answer one anticipated one: "Is FDA considering the First Amendment regarding adverting, promotion, and labeling?" Answer: "Yes, we are working on it."

For more on FDLI's Annual Meeting, please see our subsequent blog here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions